Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TransMedics (TMDX) Shares Outstanding (Weighted Average) (2018 - 2025)

TransMedics has reported Shares Outstanding (Weighted Average) over the past 8 years, most recently at $34.0 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $34.0 million for Q4 2025, up 2.3% from a year ago — trailing twelve months through Dec 2025 was $34.0 million (up 2.3% YoY), and the annual figure for FY2025 was $34.0 million, up 2.3%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $34.0 million at TransMedics, roughly flat from $34.1 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for TMDX hit a ceiling of $34.1 million in Q3 2025 and a floor of $27.4 million in Q1 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $32.5 million (2023), compared with a mean of $31.2 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): grew 28.96% in 2021 and later grew 1.52% in 2024.
  • TransMedics' Shares Outstanding (Weighted Average) stood at $27.6 million in 2021, then increased by 7.02% to $29.6 million in 2022, then rose by 10.02% to $32.5 million in 2023, then increased by 2.19% to $33.2 million in 2024, then grew by 2.3% to $34.0 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $34.0 million (Q4 2025), $34.1 million (Q3 2025), and $33.8 million (Q2 2025) per Business Quant data.